PRECOS partners RCT for cancer therapy research
The parntership allows PRECOS to validate RCT’s existing research using its validated patient relevant cancer models like in vitro 2D and 3D assays, in vivo therapeutic evaluations and
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.